Sinocelltech Group (688520) Fair Value & Analysis
Healthcare · CN · Market cap 16.3B CNY
Fair value as of: Jul 12, 2026
From 3 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥1.23 to ¥5.54 (+350.4%) since Jun 24, 2026. Share price +9.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥33.00 – ¥85.63 · fair‑value band ¥2.40 – ¥10.05 · the ¥37.37 price screens above the ¥5.54 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sinocelltech Group (688520) currently trades at ¥37.37, while our model-based Fair Value estimate is ¥5.54 — implying the stock looks roughly 85.2% overvalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Sinocelltech Group generated revenue of 1.4B CNY at a net margin of -59.0%. Revenue declined 37.8% year over year. Net debt stands at 1.8B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥2.40 (bear case) to ¥10.05 (bull case); at ¥37.37, the current price sits above that range. The share trades about 58% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -85%, 688520 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sinocelltech Group reported revenue of ¥1.6B in FY2025 versus ¥134M in FY2021, a compound +84.6%/yr. Reported net income was −¥553M in FY2025.
Is 688520 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sinocelltech Group (688520) undervalued?
What is the fair value of 688520?
What is the quality score of 688520?
What is the revenue of Sinocelltech Group (688520)?
What is the net profit margin of 688520?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Sinocelltech Group analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.